<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>With significant improvements in the rates of graft rejection and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-vs-host disease</z:e>, bone marrow transplantation remains the therapy of choice for the young <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> patient with an HLA-matched related donor </plain></SENT>
<SENT sid="1" pm="."><plain>While immunosuppressive therapy can induce responses in a significant proportion of patients, long-term follow-up studies have demonstrated a high rate of relapses and evolution to malignant clonal hematopoietic disorders </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, this therapeutic option should be considered for patients who are not transplant candidates </plain></SENT>
<SENT sid="3" pm="."><plain>The potential roles for hematopoietic growth factors and alternative marrow donors needs to be further defined </plain></SENT>
</text></document>